Your browser doesn't support javascript.
loading
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
Tu, Ya-Ping; Hanze, Eva; Zhu, Fengying; Lagraauw, H Maxime; Sloss, Callum M; Method, Michael; Esteves, Brooke; Westin, Eric H; Berkenblit, Anna.
Affiliation
  • Tu YP; Clinical Pharmacology, ImmunoGen, Waltham, Massachusetts, USA.
  • Hanze E; qPharmetra LLC, Stockholm, Sweden.
  • Zhu F; Bioanalysis, ImmunoGen, Waltham, Massachusetts, USA.
  • Lagraauw HM; qPharmetra LLC, Nijmegen, The Netherlands.
  • Sloss CM; Translational Science, ImmunoGen, Waltham, Massachusetts, USA.
  • Method M; Clinical Development, ImmunoGen, Waltham, Massachusetts, USA.
  • Esteves B; Clinical Development, ImmunoGen, Waltham, Massachusetts, USA.
  • Westin EH; Clinical Development, ImmunoGen, Waltham, Massachusetts, USA.
  • Berkenblit A; Clinical Development, ImmunoGen, Waltham, Massachusetts, USA.
Br J Clin Pharmacol ; 90(2): 568-581, 2024 02.
Article in En | MEDLINE | ID: mdl-37872122
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Immunoconjugates / Antibodies, Monoclonal, Humanized / Maytansine Limits: Female / Humans Language: En Journal: Br J Clin Pharmacol Year: 2024 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Immunoconjugates / Antibodies, Monoclonal, Humanized / Maytansine Limits: Female / Humans Language: En Journal: Br J Clin Pharmacol Year: 2024 Type: Article Affiliation country: United States